The Biden administration said it would have saved $6 billion had the new prices been in effect last year.
Category: Drugs (Pharmaceuticals)
-
Hot Summer Threatens Efficacy of Mail-Order Medications
The temperatures inside delivery trucks can reach twice the recommended threshold, but federal rules on drug storage conditions do not apply to the booming world of mail-order delivery.
-
F.D.A. Declines to Approve MDMA Therapy, Seeking More Study
The agency said there was insufficient data to allow the use of a treatment for PTSD that involves the drug known as Ecstasy, according to the company seeking approval.
-
Veterans and Lawmakers Lobby for Approval of MDMA Therapy
The F.D.A. is poised to rule on the therapeutic use of the club drug Ecstasy, a potential watershed moment in the nascent field of psychedelic medicine.
-
Executives Depart Cassava, Maker of Disputed Alzheimer’s Drug
The chief executive and a lead scientist stepped down weeks after a federal grand jury filed fraud charges against a research collaborator.
-
E.U. Court Rebukes European Commission Over Covid Vaccine Contracts
The court ruled that the European Commission wrongly withheld information, casting a shadow on its leader, Ursula von der Leyen, before a crucial vote on her future.
-
F.T.C. Says Middlemen Seem to Drive Up Drug Prices
In a report, the regulator sharply criticized pharmacy benefit managers, a reversal from its longstanding hands-off approach to policing the companies.
-
Malaria Vaccine Rollout to Africa Is a Cautionary Tale
After years of delay, millions of malaria vaccines are being supplied to children in Africa. Tens of thousands died waiting.
-
New Drug Approved for Early Alzheimer’s
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
-
Embattled Alzheimer’s Researcher Is Charged With Fraud
Hoau-Yan Wang, a professor at City College, published studies supporting simufilam, now in advanced clinical trials.
-
Deaths Linked to Japanese Supplement Suddenly Rise to 80
The case, involving a supplement intended to reduce cholesterol, has put attention on how companies are allowed to self-report claims about their products.